1. Home
  2. BVFL vs IMUX Comparison

BVFL vs IMUX Comparison

Compare BVFL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BVFL

BV Financial Inc.

N/A

Current Price

$22.12

Market Cap

176.4M

Sector

Finance

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.22

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVFL
IMUX
Founded
1873
2016
Country
United States
United States
Employees
N/A
66
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.4M
155.8M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
BVFL
IMUX
Price
$22.12
$7.22
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $43.09
AVG Volume (30 Days)
15.6K
★ 382.7K
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
31.19
★ 38.00
EPS
★ 0.55
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$41.07
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.84
$0.51
52 Week High
$22.59
$17.43

Technical Indicators

Market Signals
Indicator
BVFL
IMUX
Relative Strength Index (RSI) 66.34 33.34
Support Level $20.36 $6.35
Resistance Level N/A $8.60
Average True Range (ATR) 0.40 0.65
MACD 0.09 0.17
Stochastic Oscillator 97.62 36.89

Price Performance

Historical Comparison
BVFL
IMUX

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. It operates in one segment commercial banking. The company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: